The aim of this project is to analyze the macrophage transcriptome and protein markers of Amyotrophic Lateral Sclerosis (ALS) patients compared to controls (non-affected individuals, patients with other motor impairments) and asymptomatic ALS gene carriers, to find new pathways for therapeutic targets and disease biomarkers.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria:
* Agree to participate in this research and have signed an informed consent
* Be able to understand the objectives and procedures of the study
* Be affiliated to French social security or equivalent
* Meet one of the criteria below:
(i) Be affected by Amyotrophic Lateral Sclerosis (ALS) definite, probable or possible (El Escorial criteria) sporadic SALS (no known history in the family) or familial FALS (at least one other member of the family affected), (ii) not being affected by ALS but having a close relative who has or has been diagnosed with ALS and has or is a carrier of a known mutation causing ALS and has consented to a genetic analysis, (iii) Have a motor impairment including the following pathologies: Motor neuropathy, myopathy, Myositis, Spastic paraplegia, Cram / fasciculation syndrome, Chronic inflammatory polyradiculitis, somatization disorder, Anterior spinal artery syndrome, encephalitis, myelitis, Peroneal neuropathy, cervical myelopathy with radiculopathy, spinocerebellar ataxia, Kennedy disease, Spinal atrophy, Hereditary distal motor neuropathy.
(iv) be accompanying a person with ALS or other motor impairment that is followed by one of the doctors from the ALS referral center at the Pitié-Salpêtrière hospital or by a neurologist from the neurophysiology department at the Pitié-Salpêtrière hospital.
Exclusion Criteria:
* Be subjected to a legal protection measure (safeguard of justice, curatorship or guardianship)
* Refusing to participate in the study
* Whose condition, in the opinion of the doctor, is incompatible with blood draw or participation in research
* Being pregnant or breastfeeding
Primary outcome measure(s)
Measure of transcriptome differences between the ALS group and the 3 other groups of participants. — 5 years Will be considered different modulation superior or equal to 1.5 fold with a statistical value of p\<0.05.
Trial sites (1)
Facility
City
Region
Status
Département de Neurologie, Hôpital de la Pitié-Salpêtrière
Paris
France
Recruiting
More Institut National de la Santé Et de la Recherche Médicale, France trials in France
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.